ArticleJHEP reports : innovation in hepatology2026
Comparative evaluation of regression and machine-learning models for hepatocellular carcinoma risk stratification across diverse aetiologies.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial Intelligence in Hepatocellular Carcinoma: Current Applications, Clinical Performance, and Barriers to Implementation.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsWe aimed to develop machine learning (ML) models for hepatocellular carcinoma (HCC) risk stratification in patients with cirrhosis and to test their ability to identify those with an annual HCC incidence >3%, for whom more intensive surveillance may be justified.
methodsData from three prospective cohorts (ANRS CO12 CirVir, CO22 Hepather, APHP CIRRAL) were analyzed. All patients underwent semiannual ultrasound surveillance and were randomly split into training and validation sets. HCC incidence was evaluated using a competing risk framework. A single tree (ST) model was developed using conditional decision trees, while random forest (RF) models were built by aggregating 1,000 trees. A deep neural network (DNN)-based survival model was also applied. ML model performance was compared with established regression-based scores: aMAP (age-male-ALBI-platelets) and FASTRAK (FAST-MRI for HCC suRveillance in pAtients with high risK of liver cancer).
resultsAmong 4,867 patients with non-viral cirrhosis or resolved/controlled viral cirrhosis, 294 (9.2%) developed HCC over a median follow-up of 61.5 months (annual incidence: 1.99%). The ST model identified four key predictors, generating five distinct risk groups. These included patients with mildly impaired liver function or those with elevated GGT and low platelet counts. The RF and DNN approaches confirmed ST findings and delineated complex interactions among predictors. Performance metrics (C-index, Brier score, decision curve analysis) showed no significant advantage of ML models over aMAP and FASTRAK. Calibration was consistent across models. ML models identified higher proportions of patients with an annual HCC incidence >3% (ST 44%; DNN 37%; RF 30%) compared with aMAP (36%) and FASTRAK (29%).
conclusionsML-based algorithms did not outperform traditional risk scores but provided novel insights into variable interactions and helped identify clinically relevant patient subgroups with differing HCC risk profiles. IMPACT AND IMPLICATIONS: Accurate stratification of hepatocellular carcinoma risk in cirrhosis is essential to optimize surveillance strategies, and this study provides a scientific rationale for exploring machine learning approaches to capture complex, non-linear interactions among clinical variables beyond traditional regression models. Although machine learning did not improve predictive performance over established scores, it revealed clinically meaningful risk subgroups defined by liver function, platelet count, and GGT, underscoring its value as an interpretative and hypothesis-generating tool. These results are particularly relevant for hepatologists and clinical researchers seeking to refine risk-adapted surveillance and to inform the design of future models or trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.